ACRES: ‘Help is needed at sites to overcome the fractured nature of current processes and procedures’

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Gajus)
(Image: Getty/Gajus)

Related tags: Clinical research, Clinical data, Clinical research sites, Data integrity, Data management, Quality control

The Alliance for Clinical Research Excellence and Safety (ACRES) has released a global quality standard for clinical research sites aimed at increasing data accuracy and integrity.

The new standard results from a multi-stakeholder effort led by ACRES as part of its foundational Site Accreditation Standards Initiative (SASI)​ and is available for public review and comment until October 31, 2018.

ACRES-QC S001

The ACRES Quality Continuum Standard for the Quality Management of Clinical Research Sites (ACRES-QC S001:2018)​ has several sections and addresses: Clinical research site management and leadership; quality; risk; a people-centered workforce; person-centered care for clinical trial participants; clinical trial facility; evaluation/assessments and audits; and clinical research trial-specific data.

The standard will be “pressure tested” at selected sites during the comment period with details expected later this year and pilot testing plans slated for early 2019.

Standards

Drug development performance is not improving, “or is only improving piecemeal, in silos,”​ said Mary Tobin, PhD, chief strategy officer, ACRES.

As Tobin explained, the fragmented nature of policies, procedures, and processes burdens sites and creates inefficiencies. It also leads to high costs, prolonged time-to-market, and presents serious safety issues.

“One of the ways other high-risk industries, such as aviation, deal with this is through an integrated global system, including the development of globally shared standards,”​ she said.

For example, Tobin noted that the International Civil Aviation Organization (ICAO) develops, publishes and monitors more than 10,500 SARPs (standards and recommended practices).

“The medicines development enterprise lacks both such shared standards and mechanisms for oversight of standards if they existed,”​ she said.

Looking to the aviation industry as an example, Tobin commented – noting correlation is not causation – that in 2014 there were 3.3bn air passengers worldwide and 761 deaths. In the US, there were 4.0bn prescriptions written and 123,927 deaths, according to US Food and Drug Administration (FDA) Adverse Event Reporting System (FAER​).

“Given most research is conducted at research sites, help is needed at sites to overcome the fractured nature of current processes and procedures,”​ explained Tobin.

If the goal is growing the number of high performing sites, she said the best way to assess performance levels is with standards: “They provide the requirements against which we can measure a site's performance and compare it.”

Accreditation

Tobin said the new Quality Standard is the result of a long process, which started in 2012. It was a global effort initiated prior to the US Institute of Medicine (IOM) Collaborative Working Group effort on US Accreditation, in which ACRES participated.

“While initially considering a range of standards domains, the team decided to create a standard for quality which provides the foundational basis for real-time site performance, harmonization, and oversight in all clinical trial site operations,”​ she said.

“ACRES has believed from the beginning that site standards and voluntary site accreditation must go hand in hand,”​ added Tobin. “Without site accreditation, there is no mechanism for ascertaining if a site is meeting the requirements set by the standard.”

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars